RESUMO
Rituximab, an anti CD20 monoclonal antibody leading to transitory B cell depletion, is used to treat a wide variety of immune system tumors and immune mediated diseases. While most of data supporting the efficacy and safety of rituximab in treating autoimmune patients is focused on the adult population, the utilization of rituximab (RTX) for a wide range of pediatric conditions is also increasing. While there are a number of published case reports, a comprehensive review of the various uses for rituximab in pediatric dermatology is lacking. To better assess the therapeutic role of rituximab in the management of skin disease in children, here we comprehensively document reported cases of use including details regarding specific treatment regimens, efficacy and safety profile. Evaluation of the data supports consideration for the initiation of rituximab at early time points in the treatment ladder, before certain diseases become refractory to conventional treatment.
J Drugs Dermatol. 2016;15(7):821-829.
Assuntos
Dermatologia/métodos , Fatores Imunológicos/administração & dosagem , Pediatria/métodos , Rituximab/administração & dosagem , Dermatopatias/tratamento farmacológico , Criança , Dermatologia/tendências , Quimioterapia Combinada , Humanos , Imunoglobulinas Intravenosas/administração & dosagem , Imunoglobulinas Intravenosas/efeitos adversos , Fatores Imunológicos/efeitos adversos , Pediatria/tendências , Rituximab/efeitos adversos , Rituximab/uso terapêutico , Sepse/induzido quimicamente , Dermatopatias/diagnóstico , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/tratamento farmacológicoRESUMO
Skin fragility is a well-established complication of isotretinoin therapy for severe or resistant acne and presents a challenge to traditional modes of epilation such as waxing. As such, other less traumatic hair removal methods are desired. Herein we present the threading technique as an alternative form of epilation for patients in whom waxing is contraindicated secondary to concerns over skin fragility.
